This call is closed
We are seeking research proposals to develop novel human cell-based systems that could provide mechanistic information to help support a weight of evidence, mode of action based evaluation of the carcinogenic potential of chemicals. New models should:
- Incorporate current knowledge of the molecular mechanisms underlying human cell transformation/carcinogenesis
- Provide information on alterations in key processes involved in carcinogenesis to inform evaluation of mechanism/mode of action, or effects on pathways involved in carcinogenicity
- Include objective measures of adverse effect
- Have the potential to support a reduction in animal use for carcinogenicity assessment
Consideration should also be given to how such a model could be used in a risk assessment (rather than hazard identification) context.
Any UK research establishment including:
Applicants should be UK-based researchers who can demonstrate that they:
Overseas researchers cannot be principal applicants but can be included as collaborators. Overseas co-applicant status can be obtained in exceptional circumstances and at the discretion of the NC3Rs; approval should be sought before applying.
The NC3Rs does not allow resubmission of previously unsuccessful proposals, unless explicitly invited by the Panel. Proposals previously declined by the NC3Rs will not be considered by another Research Council or funder within 12 months (from the date of submission to the original Research Council) unless substantially revised. More information can be found in the NC3Rs Applicant and Grant Holder Handbook.
Please note: The same or similar application cannot be considered by any other Research Council, the Health Departments or any other research funder at the same time.
This call is now closed. For information on future Strategic Award calls please sign up to the NC3Rs Newsletter for updates.
Applications are evaluated by international peer reviewers and assessed by the NC3Rs Strategic Award Panel.
The following criteria will be taken into consideration when making funding decisions:
- Relevance to the strategic call
- Potential impact on the 3Rs
- Quality of the science
- Current or future importance of the techniques to medical, biological or veterinary research
- Strategy for promoting the proposed research to the scientific community
- Expertise and track record of the team
- Relevance to the NC3Rs strategy
- Value for money
The following panel considered applications submitted to this competition.
Professor Ian Kimber (Chair)
|University of Manchester|
Dr Jim Harvey
Dr Marilyn Aardema
Dr Michael Routledge
|University of Leeds|
Dr Rafaella Corvi
Two awards were made in November 2011